---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-027111"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:54:53.292464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering

## Summary
- Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.
- CONNECT2-EDO51 Phase 2 trial for DMD initiated in UK; designed to support accelerated approval.
- FREEDOM-DM1 Phase 1 trial enrolling; preliminary data from 5 mg/kg cohort expected H2 2024.
- Cash $110.4M as of Dec 31, 2023; combined with $80M Feb 2024 offering extends runway into 2026.
- Net loss $78.6M for FY2023 vs $69.1M in FY2022; R&D expenses $68.1M.

## SEC filing metadata
- accession: 0000950170-24-027111
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/0000950170-24-027111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/pepg-20240306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-027111
- JSON: https://secwatch.observer/filing/0000950170-24-027111.json
- Plain text: https://secwatch.observer/filing/0000950170-24-027111.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 6, 2024, PepGen Inc. announced its financial results for the year ended December 31, 2023 and other business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017024027111/0000950170-24-027111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.